Matt Hay

Matt Hay currently serves as the U.S. Director of Advocacy for Metabolics - Neurofibromatosis (NF) and Hypophosphatasia (HPP) at Alexion Pharmaceuticals, Inc., where engagement with the patient community is prioritized. Previously, Matt held the position of U.S. Director of Advocacy for NF at Redux, focusing on innovative solutions in hearing care, and worked as a Development Advisor at St. Joseph Institute for the Deaf, promoting education for deaf and hard of hearing children. Matt's extensive experience also includes a long tenure at News America Marketing, where leadership in customer insights combined advertising and data analysis for numerous accounts. Currently pursuing a Doctorate in Public Health with a focus on Global Health Leadership, Matt also holds an MBA in Marketing from the Kelley School of Business and a Bachelor's degree in Marketing from Indiana University Bloomington.